Tuesday, Jan 23 2018 | Time 15:35 Hrs(IST)
image
  • Magnitude 8'2 quake off Alaska prompts tsunami warning
  • Siddaramaiah can't present full budget: Yeddyurappa
  • Tripura LF declares candidates, no major change in list
  • Reference rate fixed at 63'7722 against USD
  • Air Force Chief inspects Jodhpur base
  • Police resort to lathicharge on BJP leaders marching Naveen Nivas to demand CBI probe on Kunduli gang rape case
  • Sealing drive: Kejriwal urges Centre to bring Ordinance
  • Triple Talaq Bill conspiracy against Muslims: Owaisi
  • Day chill revisits due to overcast conditions in Kashmir
  • New UP DGP calls for effective, professional policing to improve L&O
  • SC says NIA can prove all aspects except Hadiya's marriage
  • Traders in Delhi protest against sealing
  • Four Nations Invitational Tourney: India to take on hosts New Zealand in second-leg
  • GST biggest ever tax reform in country: Venkaiah Naidu
  • About 600 kg hemp seized in Chitrakoot, two peddlers held
Science Technology Share

WHO advises Dengvaxia be used only in people previously infected with dengue

WHO advises Dengvaxia be used only in people previously infected with dengue

Kolkata, Dec 14 (UNI) Following a consultation of the Global Advisory Committee on Vaccine

Safety, the World Health Organization (WHO) finds that the dengue vaccine CYD-TDV, sold

under the brand name Dengvaxia, prevents disease in the majority of vaccine recipients but

it should not be administered to people who have not previously been infected with dengue

virus.

This recommendation is based on new evidence communicated by the vaccine’s

manufacturer (Sanofi Pasteur), indicating an increase in incidence of hospitalization and

severe illness in vaccinated children never infected with dengue.

The WHO Global Advisory Committee on Vaccine Safety considered the company’s new

results from clinical trial data analyses. Those studies indicate that increased risk of severe

dengue disease in people who have never been infected affects about 15 per cent of the

vaccinated individuals.

The magnitude of risk is in the order of about 4 out of every 1000 seronegative patients

vaccinated who developed severe dengue disease during five years of observation. The risk

of developing severe dengue disease in non-vaccinated individuals has been calculated as

1.7 per 1000 over the same period of observation.

By contrast, for the 85 per cent who have had dengue disease before immunization, there

is a reduction of 4 cases of severe dengue per 1 000 who are vaccinated.

The possibility of risk for seronegative people was raised by WHO and published in a

position paper in July 2016: “…vaccination may be ineffective or may theoretically even increase

the future risk of hospitalized or severe dengue illness in those who are seronegative at the time

of first vaccination regardless of age."

As this risk had at that time not been seen in the age groups for which the vaccine was

licensed, WHO issued a conditional recommendation, emphasizing the use of the vaccine

in populations having been previously infected with dengue virus.

To minimize illness for seronegative vaccinated people, WHO recommends enhancing

measures that reduce exposure to dengue infection among populations where the vaccine

has already been administered.

For vaccine recipients who present with clinical symptoms compatible with dengue virus

infection, access to medical care should be expedited to allow for proper evaluation,

identification, and management of severe forms of the disease.

Dengue is a mosquito-borne flavivirus disease that has spread to most tropical and many subtropical areas. The disease is caused by four closely related viruses. There is no specific

dengue treatment and prevention is mainly limited to vector control measures. A safe and

effective dengue vaccine would therefore represent a major advance in the control of the

disease.

CYD-TDV is a live attenuated tetravalent vaccine made using recombinant DNA technology

and is administered in three phases separated by six-month intervals. It became commercially available in 2016 and is currently licensed in 19 countries.

UNI BM SJC

More News
Middle East respiratory syndrome, a viral respiratory disease

Middle East respiratory syndrome, a viral respiratory disease

19 Jan 2018 | 1:30 PM

Kolkata, Jan 19 (UNI) Middle East respiratory syndrome (MERS) is a viral respiratory disease
caused by a novel coronavirus (Middle East respiratory syndrome coronavirus, or MERS‐CoV)
that was first identified in Saudi Arabia in 2012.

 Sharesee more..

Science has to be people centric: Dr Harsh Vardhan

18 Jan 2018 | 1:08 PM

Hyderabad, Jan 18 (UNI) Union Minister for Science and Technology Harsh Vardhan has said that the Science has to be people centric and its benefits would deliver to the people.

 Sharesee more..
Greater efforts needed to meet international family planning goals

Greater efforts needed to meet international family planning goals

17 Jan 2018 | 12:32 PM

Kolkata, Jan 17 (UNI) Women and girls have a human right to choose whether and when to become pregnant.

 Sharesee more..
TN pioneer in organ transplants, other states should follow it : Venkaiah

TN pioneer in organ transplants, other states should follow it : Venkaiah

16 Jan 2018 | 5:13 PM

Chennai, Jan 16 (UNI) Observing that Tamil Nadu was a pioneering state in organ transplantation in the country, Vice President M Venkaiah Naidu on Tuesday said other states should emulate it in providing affording medical care to the people.

 Sharesee more..
Echinococcosis, a parasitic disease that occurs in two main forms in humans

Echinococcosis, a parasitic disease that occurs in two main forms in humans

13 Jan 2018 | 12:16 PM

Kolkata, Jan 13 (UNI) Echinococcosis is a parasitic disease that occurs in two main forms in humans: cystic echinococcosis (also known as hydatidosis) and alveolar echinococcosis, caused by the tapeworms Echinococcus granulosus and Echinococcus multilocularis, respectively.

 Sharesee more..
image